Olga Borges leads a research group on "vaccines and adjuvants" within the biotechnology field at CNC (Center for Neuroscience and Cell Biology). Her research projects aim not only at developing adjuvants for subunit vaccines but also for DNA and mRNA vaccines. Particularly, the group has several objectives, including developing therapeutic vaccines and vaccines that can be effective through different administration routes from the conventional route, such as oral and intranasal administration. According to Google Scholar, researcher Olga Borges is the author of 84 scientific documents cited 2399 times, with an h-index of 26 and an i10-index of 46. Scopus lists 61 documents authored by her with a total of 1885 citations and an h-index of 25. Olga Borges was included in the "World's Top 2% Scientist 2021 and 2022" list, the most influential scientists, as disclosed by the Elsevier editorial group. She contributed to the writing of 81 publications across various categories: editor of 1 book, author of 7 book chapters, 61 articles in ISI journals (4 submitted), author of 1 guideline, 2 articles in Portuguese journals, and 9 congress abstracts published in journals. Additionally, her scientific work has been presented in 57 oral presentations at congresses, symposiums, and workshops, and in 61 congress posters. Her contribution to these publications can be considered highly relevant, as she is the first author/corresponding author/last author in 75% of ISI articles and 71% of book chapters. It's worth noting that 80% of the publications in ISI journals correspond to laboratory research conducted entirely or largely in her laboratory, while the rest are review works. As the principal investigator (PI), she secured funding for her research group through 6 competitive projects she wrote and submitted to various funding entities: 2 projects from FCT (Portuguese Foundation for Science and Technology), 1 transnational FCT PROSAFE project involving research laboratories from 2 other countries (Romania and Switzerland), 1 project from Gilead Sciences, and 2 grants/prizes from private entities. In total, she has been responsible for securing €565,939.55 in funding through these 6 projects. She also directly contributed to the writing effort of 8 projects that led to the awarding of FCT doctoral scholarships, each for 4 years, as well as scholarships granted by CAPES (Brazil) for 1-year postdoc internships (3 students) and sandwich doctoral students (3 students). As a researcher, she is also involved in 12 other competitive projects funded and being developed at the University of Coimbra. She has received repeated invitations to be part of the editorial boards of journals. In total, she has served on 9 journals, including Vaccines (MDPI) and Frontiers, for which she has contributed to 6 special issues and is a regular editor for Vaccines. Olga Borges is a lecturer at the Faculty of Pharmacy of the University of Coimbra, where she has been teaching for 25 years. She has taught theoretical, theoretical-practical, and laboratory classes in 9 different curricular units and has been the coordinator of 5 curricular units, notably the curricular units she is currently teaching: Vaccine and Adjuvant Production Technology (optional); Pharmaceutical Technology II; Regulation in Drug Development. She has supervised over 43 final course projects (monographic review work), supervised 12 scientific master's students (completed), and has 6 master's students in the laboratory conducting scientific work. She has supervised 8 doctoral thesis students. She was the advisor for 5 Ph.D. students with completed theses defended at the University of Coimbra and 3 Brazilian students with completed sandwich doctoral degrees defended at Brazilian universities. Additionally, she has 3 Ph.D. students who will complete their theses in the next 1-2 years and 1 student who is just beginning. She also supervised 5 post-docs.